Clinical trial
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus…
NCT00429871 · Hellenic Oncology Research Group, Other · Completed
Key facts
| NCT number | NCT00429871 |
|---|---|
| Title | Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer |
| Official title | A Multicenter Randomized Comparative Study of Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine Combinations as First Line Treatment of Metastatic Breast Cancer |
| Lead sponsor | Hellenic Oncology Research Group, Other |
| Collaborators | University Hospital of Crete |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Capecitabine, Epirubicin |
| Enrollment | 272 |
| Start date | May 1, 2002 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 1, 2007 |
| Last update posted | May 29, 2009 |
| Countries | Greece |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: